Defining RNA oligonucleotides that reverse deleterious phase transitions of RNA-binding proteins with prion-like domains

Read full text
Authors: Lin Guo, Jacob R. Mann, Jocelyn C. Mauna, Katie E. Copley, Hejia Wang, Jack D. Rubien, Cristian A Bergmann, Jenny Carey, Jessica Merjane, Marilyn Ngo, Jiazhen Xu, Hana M. Odeh
+21 more JiaBei Lin, Bo Lim Lee, Laura R. Ganser, Emma Robinson, Kevin M. Kim, Anastasia C. Murthy, Tapas Paul, Bede Portz, Amanda M. Gleixner, Zamia Diaz, Ashleigh Smirnov, George M. Padilla, Ellen Lavorando, Carolann Espy, Yulei Shang, Eric J. Huang, Alessandra Chesi, Nicolas L. Fawzi, Sua Myong, Christopher J. Donnelly, James Shorter
Cited by: 7
References: 119

Abstract

RNA-binding proteins (RBPs) with prion-like domains (PrLDs), such as FUS and TDP-43, condense into functional liquids, which can transform into pathological fibrils that underpin fatal neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD). Here, we define short RNAs that prevent FUS fibrillization by promoting liquid phases and distinct short RNAs that prevent and reverse FUS condensation and fibrillization. These activities require interactions with multiple RNA-binding domains of FUS and are encoded by RNA sequence, length, and structure. We define a short RNA that dissolves cytoplasmic FUS aggregates, restores nuclear FUS, and mitigates FUS toxicity in optogenetic models and ALS patient-derived motor neurons. Another short RNA dissolves cytoplasmic TDP-43 aggregates, restores nuclear TDP-43, and mitigates TDP-43 toxicity. Since short RNAs can be effectively delivered to the human brain, these oligonucleotides could have utility for ALS/FTD and related disorders.

Fields of Study & Subjects

Amyotrophic Lateral Sclerosis Research RNA Research and Splicing Prion Diseases and Protein Misfolding

Publication details

Journal / source
Molecular Cell
Publisher
Elsevier BV
Volume
86
Issue
1
Pages
114–134.e10
Publication date
1 January 2026
Language
EN